https://insightsemerge.com/press-releases/johnson-and-johnson-announces-icotyder-icotrokinra-delivers-significant-improvement-inInsights Emergeen2026-11-07T15:18:46.079ZJohnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide https://insightsemerge.com/press-releases/hengrui-pharma-and-braveheart-bio-present-data-from52-week-open-label-extension-of-phaseInsights Emergeen2026-11-06T20:36:29.123ZHengrui Pharma and Braveheart Bio Present Data from52-Week Open-Label Extension of Phase 2 Studyof HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 https://insightsemerge.com/press-releases/bausch-healths-gastroenterology-business-salix-to-present-new-data-on-cirrhosis-trendsInsights Emergeen2026-11-06T12:20:25.000ZBausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 https://insightsemerge.com/press-releases/this-announcement-contains-inside-informationInsights Emergeen2026-11-05T22:15:42.111ZTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION https://insightsemerge.com/press-releases/shoulder-innovations-reports-third-quarter-2026-financial-results-and-raises-full-yearInsights Emergeen2026-11-05T21:15:25.188ZShoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook